Summary of COVID-19 danicopan studies

1. Beigel et al., ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

201 patient danicopan late treatment RCT: 43% higher mortality (p=0.34), 17% higher ventilation (p=0.69), 54% worse recovery (p=0.01), and 37% worse improvement (p=0.06).
RCT 201 hospitalized COVID-19 patients showing increased risk with danicopan treatment, with statistical significance for time to sustained recovery.
Apr 2022, NCT04988035, https://clinicaltrials.gov/study/NCT04988035, https://c19p.org/beigel2